Literature DB >> 9355208

Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies.

C Belizna1, J W Tervaert.   

Abstract

OBJECTIVE: To characterize the putative target antigens for antiendothelial cell antibodies (AECA), the possible pathophysiological role of AECA, and the clinical value of these antibodies as markers of disease activity.
METHODS: A structured literature search was done using Medline in combination with a manual search. Two physicians reviewed all articles of special interest.
RESULTS: AECA are a heterogenous group of antibodies directed against a variety of antigen determinants on endothelial cells (EC). The EC antigens can be constitutively expressed, constitutively expressed and modulated by cytokines, or cryptic. In addition, antigen determinants for AECA may also be molecules that adhere to EC ("planted" antigens). However, many AECA antigens are currently not well characterized. AECA are detected in a wide variety of inflammatory disorders. Although probably of limited value in disease diagnosis, the detection of these antibodies may be valuable in following disease activity. In several diseases such as systemic lupus erythematosus and systemic vasculitis, high AECA titers are found during active disease whereas lower titers or disappearence of AECA have been reported during remission. The correlation between changes in AECA titers and disease activity suggests an important role for AECA in processes in which vessel wall damage occurs, although it does not exclude the possibility that AECA are an epiphenomenon of vascular injury. Several recent in vitro studies support a role of AECA in the pathophysiology of these inflammatory disorders. AECA may play a role in the pathophysiology by inducing activation of EC resulting in upregulation in the expression of endothelial adhesion molecules and/or secretion of chemoattractants and cytokines. An alternative mechanism by which AECA could be a trigger in the pathogenesis of some diseases is complement dependent cytotoxicity (CDC) and/or antibody dependent cellular cytotoxicity (ADCC). In experimental animal models, antibodies to antigenic determinants expressed on EC were capable of inducing vascular injury.
CONCLUSION: AECA represent a heterogenous group of antibodies directed against a variety of antigenic determinants on EC. They are present in a variety of inflammatory disorders. The detection of these antibodies may be valuable in following disease activity. Further characterization of putative antigens is needed to better understand their pathophysiological role.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355208     DOI: 10.1016/s0049-0172(97)80010-8

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  16 in total

1.  Detection of antiendothelial cell antibodies by an enzyme-linked immunosorbent assay using antigens from cell lysate: minimal interference with antinuclear antibodies and rheumatoid factors.

Authors:  Christian Drouet; Marie-France Nissou; Denise Ponard; Josiane Arvieux; Chantal Dumestre-Pérard; Philippe Gaudin; Bernard Imbert; Christian Massot; Françoise Sarrot-Reynauld
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 2.  Antiendothelial cell antibodies in vasculitis and connective tissue disease.

Authors:  C Belizna; A Duijvestijn; M Hamidou; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

Review 3.  Cogan's syndrome--clinical guidelines and novel therapeutic approaches.

Authors:  Oshrat E Tayer-Shifman; Ophir Ilan; Hodaya Tovi; Yuval Tal
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 4.  Distinguishing Susac's syndrome from multiple sclerosis.

Authors:  Katherine A Buzzard; Stephen W Reddel; Con Yiannikas; D Sean Riminton; Michael H Barnett; Todd A Hardy
Journal:  J Neurol       Date:  2014-12-30       Impact factor: 4.849

Review 5.  Immunopathogenesis of vasculitis.

Authors:  Raquel Cuchacovich
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

6.  The Level of IgA Antibodies to Endothelial Cells Correlates with Histological Evidence of Disease Activity in Patients with Lupus Nephritis.

Authors:  Ayako Kondo; Kazuo Takahashi; Tomohiro Mizuno; Akihiro Kato; Daisuke Hirano; Naoki Yamamoto; Hiroki Hayashi; Shigehisa Koide; Hiroshi Takahashi; Midori Hasegawa; Yoshiyuki Hiki; Shunji Yoshida; Keiji Miura; Yukio Yuzawa
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

7.  Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases.

Authors:  M Okawa-Takatsuji; S Aotsuka; S Uwatoko; M Takaono; K Iwasaki; M Kinoshita; M Sumiya
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

8.  Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension?

Authors:  S J Arends; J G M C Damoiseaux; A M Duijvestijn; L Debrus-Palmans; M Vroomen; K A Boomars; H-P Brunner-La Rocca; C P M Reutelingsperger; J W Cohen Tervaert; P van Paassen
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

Review 9.  Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases.

Authors:  Philippe Guilpain; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

10.  The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schönlein purpura.

Authors:  Y-H Yang; S J Wang; Y-H Chuang; Y-T Lin; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.